Rasonque FDA Approval Lifts Revolution Medicines Stock 0.8% at $45.7 Billion Valuation
Rasonque won U.S. approval Wednesday, giving Revolution Medicines, Inc. its first commercial product. The stock rose 0.77% to $213.01 at 11:55 a.m. EDT.
Biohaven Shares Surge 25% Following Court’s $4 Million MODA Ruling
Shares of Biohaven jumped on Wednesday after a federal court finalized its win in a trade-secret lawsuit, boosting the clinical-stage drugmaker’s market capitalization by about $553 million.
Biohaven • NYSE:BHVN
MODA Judgment: What the 25% Rally Prices
The cash award is small. Platform ownership and pivotal-stage optionality drove the read-through.
Market snapshot
August 26, 2026, 14:10 EDT
August 26, 2026, 14:10 EDT
Share price
$18.04
+$3.66 • +25.47%
Volume
10.34M
3.61× three-month average
Market value
$2.73B
About $553M added intraday
Analyst view
1.8
Yahoo classification: Buy
One-month price path
Intraday Aug. 26 price; earlier points use daily closes. The session high was $18.24.
Judgment math
The market-value response was about 138× the total award. Investors treated the judgment as platform validation, not income.
Financial frame
| Metric | Latest |
|---|---|
| Cash, securities and restricted cash | $270.5M |
| Q2 R&D expense | $100.8M |
| Q2 net loss | $137.3M |
| H1 operating cash use | $235.0M |
| Revenue | None |
Company guidance says existing resources fund at least one year. Further capital is still expected before meaningful product revenue.
Extracellular degrader milestones
Jun. 29
BHV-1300 Phase 3 began
Pivotal Graves’ disease trial enrolled its first patient.
Pivotal Graves’ disease trial enrolled its first patient.
2H 2026
BHV-1400 pivotal start
IgA nephropathy program targets registrational development.
IgA nephropathy program targets registrational development.
2H 2026
Other readouts
Obesity topline and epilepsy data remain separate valuation catalysts.
Obesity topline and epilepsy data remain separate valuation catalysts.
Evidence investors are underwriting
| Program | Target / disease | Reported signal | Stage |
|---|---|---|---|
| BHV-1300 | Pathogenic IgG / Graves’ | >80% mean antibody reduction at week 12 | Phase 3 |
| BHV-1400 | Gd-IgA1 / IgAN | ~70% reduction within first month | Pivotal start planned |
These are early biomarker findings. They do not establish clinical benefit or approval.
Risk watch
Legal: RA Capital has denied wrongdoing and signaled post-trial and appellate remedies plus patent counterclaims.
Clinical: The stock’s value depends on pivotal outcomes, safety, enrollment and regulatory review.
Financing: Pre-revenue cash use keeps dilution and debt terms material.
Sources: Biohaven releases dated Aug. 25 and Aug. 10, 2026; Biohaven Form 10-Q; Yahoo Finance market data; New Haven Register. Calculations use 151.04 million shares outstanding. Time-sensitive figures are stamped above.
Rasonque approval dashboard
Revolution Medicines moves from trial risk to launch risk
NASDAQ:RVMD · PRODUCT/COMMERCIAL CATALYST
Market data: August 26, 2026
11:55 EDT / 17:55 Europe/Warsaw
11:55 EDT / 17:55 Europe/Warsaw
RVMD price
$213.01
+$1.63 · +0.77%
Market value
$45.65B
≈ $351M added today
Session range
8.3%
$198.91 low · $216.50 high
Volume by 11:55
1.10M
64% of 1.71M daily average
Session price map
Range positions are scaled from the verified session low and high. This is not a minute-by-minute price chart.
What changed
Rasonque is now a first-in-class, once-daily oral RAS inhibitor for certain adults with metastatic pancreatic cancer.
First product revenueNow possible
PricingNot disclosed
AvailabilityNot disclosed
Expanded-access patients2,000+
Phase 3 survival comparison
Rasonque median overall survival13.2 months
Standard chemotherapy6.7 months
Absolute improvement+6.5 months
Relative improvement+97%
Trial population500 adults
Valuation versus operating base
| Metric | Amount | Ratio to market cap |
|---|---|---|
| Quoted market value | $45.65B | 100% |
| Cash and securities, June 30 | $3.94B | 8.6% |
| 2026 operating-expense midpoint | $2.15B | 4.7% |
| Q2 operating expenses | $505.1M | 1.1% |
| Q2 net loss | $644.4M | 1.4% |
Cash equals 1.83× the midpoint of the current annual expense guide. It is not a formal runway estimate.
Analyst expectations
Buy ratings18
Hold ratings1
Average target$222.89
Implied upside4.6%
Target range$179–$291
Based on Google Finance’s 19-analyst, three-month set at the market-data timestamp.
What the valuation requires
Launch pricing and reimbursementNear term
Initial prescriptions and net salesNext reports
First-line pancreatic expansionPhase 3
RAS-mutant lung cancer readoutExpected 2027
Broad peak-sales estimate>$20B
The >$20B estimate assumes success beyond today’s approved patient group; current market value is about 2.3× that figure.
Catalyst timeline
Phase 3 survival data established the approval case.
Company reported U.S. launch readiness and $3.94B liquidity.
FDA approved Rasonque for the initial metastatic setting.
Pricing, availability, reimbursement and prescription uptake.
Risk monitor
Commercial
Pricing remains unknown. Slow coverage decisions can defer revenue even after approval.
Execution
Manufacturing limits or weak real-world uptake would pressure launch estimates.
Valuation
The average analyst target offers only 4.6% upside. Failed expansion trials would narrow the revenue base.
Investor bridge
Approval creates the first direct sales channel for Revolution Medicines. The financial test is whether Rasonque’s launch and later-label expansion can grow into a $45.65 billion valuation while annual operating expenses run near $2.15 billion.
CRISPR Therapeutics Stock Rises 6.7% Before CTX310 Data as $80 Target Signals 31% Upside
CRISPR Therapeutics AG rose 6.70% before a late-breaking CTX310 presentation. The stock closed Tuesday at $60.90. Volume reached 2.08 million shares.
NASDAQ: CRSP · CTX310 event monitor
CRISPR Therapeutics
Investors paid for clinical optionality before the August 28 durability update.
U.S. market closedClose: Aug. 25, 2026, 16:00 EDT
After hours: $60.77, −0.21% at 17:01 EDT
After hours: $60.77, −0.21% at 17:01 EDT
Close
$60.90
Aug. 25, 16:00 EDT
Daily move
+6.70%
+$3.83 per share
Quoted value added
≈$370M
Estimate using ≈96.7M shares
Volume
2.08M
1.24× 1.69M average
Market value
$5.89B
At Aug. 25 close
Seven-session price path
Daily closes, Aug. 17–25, 2026. The latest move recaptured the prior week's high.
What moved: Citizens reiterated Market Outperform and an $80 target before the CTX310 late-breaking presentation. The target stood 31.4% above Tuesday's close.
Catalyst clock
The valuation test shifts from anticipation to durability.
Citizens kept an $80 target. CRSP closed 6.70% higher on 1.24× average volume.
Late-breaking ESC presentation. The scheduled 10:30 EDT session covers Phase 1a CTX310 durability.
Management expects another CTX310 update as Phase 1b evaluates additional patients and dose selection.
The key question
Can one-time ANGPTL3 editing preserve lipid reductions without new safety signals? Durable effects would strengthen the cardiovascular-platform case. Short-lived effects would weaken it.
CTX310 efficacy seen so far
Mean reductions at the highest tested dose in initial Phase 1 data; investigational treatment, not an approved product.
Maximum individual reductions were 89%, 84% and 87%, respectively. Initial analysis covered 15 participants with average follow-up of at least 60 days. No treatment-related serious adverse events or grade 3-or-higher liver-transaminase changes were reported.
Balance-sheet buffer
Reported for the quarter ended June 30, 2026.
Cash + securities$2.36B40.1% of market value
Q2 net loss$91.2MGAAP
Simple runway≈26 qtrsCash ÷ one quarter's loss
Q2 revenue$10.2MCollaboration revenue
R&D$67.2MQ2 expense
Convertible proceeds$585.4MIncluded in liquidity build
The 26-quarter figure is a mechanical ratio, not management guidance. Clinical spending, milestones and working capital will change the actual runway.
Analyst valuation range
Targets available Aug. 25, 2026; upside or downside versus the $60.90 close.
| Reference | Target | Implied move |
|---|---|---|
| Citizens | $80.00 | +31.4% |
| S&P Global average | $87.56 | +43.8% |
| S&P Global median | $80.00 | +31.4% |
| S&P Global low | $44.00 | −27.8% |
BUY S&P Global consensus across 22 analysts. Targets are opinions, not forecasts.
Commercial anchor: CASGEVY
Vertex leads commercialization; economics are shared with CRISPR Therapeutics.
Q2 revenue$76MReported by Vertex
Sequential growth+78%Quarter over quarter
Annual growth+151%Year over year
Vertex and CRISPR Therapeutics share CASGEVY profits and costs 60%/40%. The approved therapy provides commercial validation, but CTX310 has a different delivery method, target and risk profile.
Risk monitor
The stock move came before detailed durability data.
- CTX310 remains in early clinical development and generates no product revenue.
- The initial sample was small. Longer follow-up could change efficacy or safety conclusions.
- Durability, dose selection, liver safety and off-target editing remain central clinical tests.
- Convertible financing supports cash runway but can create interest expense and future dilution.
- CASGEVY uptake does not guarantee success for an in-vivo cardiovascular program.
Moderna Shares Surge 14.4% After Cancer-Vaccine Repricing Boosts Valuation by $8 Billion
Moderna Inc. surged 14.36% on Tuesday to close at $158.83 after Wolfe Research raised its rating on the stock to Peer Perform from Underperform. The $19.94 increase boosted Moderna's quoted equity value by approximately $8.0 billion.
Moderna · NASDAQ:MRNA
Cancer-vaccine repricing dashboard
Stock move, valuation, trial evidence and cash runway
Market closed · Aug. 25, 2026, 16:00 EDT
Close
$158.83
Aug. 25, 2026, 16:00 EDT
One-day move
+14.36%
+$19.94 per share
Volume
49.05M
3.7× three-month average
Quoted market value
$63.41B
Aug. 25 close
Six-session price path
+152.3% vs. Aug. 18Daily close, EDTSource: market history through Aug. 25, 2026
Valuation bridge
Post-readoutMarket value added Aug. 25≈$8.0B
Market value added vs. Aug. 18≈$38.3B
Q2 2026 revenue$145M
Q2 2026 net loss-$782M
Cash and investments, June 30$6.9B
2026 year-end cash outlook$4.7B–$5.2B
Financial figures reported July 31, 2026. A $950M settlement payment followed in July.
Analyst expectations
Updated through Aug. 25S&P Global consensus: Hold, 23 analysts; average target implies 37.2% downside from Tuesday's close.
Catalyst timeline
Next evidence mattersAug. 19
Phase 3 INTerpath-001 met recurrence-free and distant-metastasis-free survival endpoints; detailed figures withheld.
Aug. 24
Barclays raised its target to $125 from $48 and kept Equal Weight.
Aug. 25
Wolfe Research upgraded MRNA to Peer Perform; shares closed 14.36% higher.
Next
Full Phase 3 presentation, regulator discussions and continued overall-survival follow-up.
Trial and peer context
Aug. 19 catalyst| Measure | Reading | Investor meaning |
|---|---|---|
| INTerpath-001 enrollment | 1,137 patients | First positive Phase 3 individualized mRNA cancer-therapy readout |
| Treatment design | Up to 34 neoantigens; nine intismeran doses | Patient-specific manufacturing adds cost and turnaround risk |
| Phase 2b five-year result | 49% lower recurrence/death risk; 59% lower distant-metastasis/death risk | Supports mechanism, but Phase 3 effect size remains undisclosed |
| Moderna reaction | +176.97% on Aug. 19 | Largest direct platform repricing |
| Merck reaction | +12.6% on Aug. 19 | Extends the Keytruda franchise opportunity |
| BioNTech reaction | about +22% on Aug. 19 | Read-through for personalized mRNA oncology |
Investor bridge
The August 25 rally added about $8.0 billion in value. Since the pre-readout close, the gain is about $38.3 billion. That premium now depends on regulatory timing, manufacturing economics and success beyond melanoma.
Risks
Hazard ratios, absolute event rates and overall-survival data are pending. Personalized production may constrain margins. Other tumors may not reproduce the melanoma result. Cash burn remains material.
Timestamp: Aug. 26, 2026, 03:07 EDT / 09:07 CESTReuters market closeTrial releaseTreatment economicsModerna Q2Analyst consensus
CRISPR Therapeutics Shares Advance 5.8% Ahead of CTX310 Results Release
Shares of CRISPR Therapeutics AG rose 5.8% on Tuesday, increasing its market capitalisation by roughly $319 million ahead of new CTX310 clinical results.
NASDAQ: CRSP · Stock move
CRISPR Therapeutics
CTX310 durability data becomes the next valuation test
Market data: Aug. 25, 2026, 12:38:56 EDT
U.S. regular session · Prices intraday
U.S. regular session · Prices intraday
Share price
$60.38
▲ $3.30 · +5.79%
Market cap
$5.84B
96.69M shares outstanding
Value added today
≈$319M
$3.30 × 96.69M shares
Citizens target
$80
+32.5% · ≈$7.74B implied cap
Intraday range and reference levels
The $80 target sits above the displayed 52-week high. Levels as of 12:38:56 EDT.
Balance-sheet and earnings frame
| Cash + marketable securities | $2.364B |
| Cash as share of market cap | 40.5% |
| Q2 revenue | $10.2M |
| Q2 R&D expense | $67.2M |
| Q2 net loss | $91.2M |
| CASGEVY Q2 global revenue | $76M |
Company data for quarter ended June 30, 2026; CASGEVY revenue is global product revenue reported by CRISPR.
Analyst map
| Firm | Latest action | Rating | Target | Implied return |
|---|---|---|---|---|
| Citizens | Aug. 25 | Market Outperform | $80 | +32.5% |
| Goldman Sachs | Aug. 10 | Hold | $55 | −8.9% |
| Bank of America | Aug. 5 | Buy | $82 | +35.8% |
| Morgan Stanley | Aug. 4 | Hold | $60 | −0.6% |
| Piper Sandler | Aug. 4 | Buy | $110 | +82.2% |
Google Finance displayed 13 analysts: eight Buy, five Hold and no Sell; average target $74.33. Implied returns use $60.38.
Catalyst clock
Aug. 25 · 12:38:56 EDTCRSP +5.79%; intraday high $61.55.
Aug. 28 · 16:30 CEST · MunichLate-breaking ESC presentation: durability of CTX310 effects.
Second half 2026Broader Phase 1b CTX310 update expected.
What the price is discounting
A durable ANGPTL3 response could add an in-vivo cardiovascular franchise beside CASGEVY. Tuesday's move capitalized that possibility before the data.
Risk check
CTX310 is early-stage. Small cohorts, safety findings or weaker durability could erase the move. Clinical value remains distinct from commercial value.
Investor bridge
$319 million gained versus $2.364 billion of liquidity. The stock's one-day market-value increase equals roughly 13.5% of reported cash and securities. Citizens' $80 target adds another $1.90 billion of implied equity value from the midday base. The August 28 data therefore tests whether investors will assign meaningful value to CTX310 before later-stage evidence.
Sources: CRISPR Therapeutics Q2 2026 business update; Google Finance; Citizens research note reported by Investing.com. Calculations may differ slightly because market capitalization and shares outstanding are rounded.
Generate Biomedicines Shares Up 12% as 103 Million-Share Placement Looms
Shares of Generate Biomedicines Inc. rose 12.3% on Tuesday ahead of its initial significant post-IPO supply challenge. The biotech company was trading at $19.90 as of 12:36 EDT.
:root{color-scheme:dark;--bg:#071018;--card:#0f1c27;--card2:#122635;--line:#263a48;--text:#edf6fb;--muted:#97adba;--cyan:#4ed7e8;--green:#55d98f;--amber:#ffc86b;--red:#ff7785}*{box-sizing:border-box}body{margin:0;background:linear-gradient(160deg,#071018,#0b1721 48%,#071018);color:var(--text);font:14px/1.45 Inter,ui-sans-serif,system-ui,-apple-system,Segoe UI,sans-serif}.dash{max-width:1140px;margin:auto;padding:22px}.top{display:flex;justify-content:space-between;gap:16px;align-items:flex-start;margin-bottom:14px}.eyebrow{color:var(--cyan);font-weight:800;letter-spacing:.12em;text-transform:uppercase;font-size:11px}h1{font-size:clamp(25px,4vw,42px);line-height:1.05;margin:5px 0}.stamp{color:var(--muted);text-align:right;font-size:12px}.grid{display:grid;grid-template-columns:repeat(12,1fr);gap:12px}.card{background:linear-gradient(145deg,var(--card),#0b1721);border:1px solid var(--line);border-radius:16px;padding:16px;box-shadow:0 10px 28px #0004}.kpi{grid-column:span 3}.wide{grid-column:span 8}.side{grid-column:span 4}.half{grid-column:span 6}.full{grid-column:1/-1}.label{color:var(--muted);font-size:11px;text-transform:uppercase;letter-spacing:.08em}.value{font-size:29px;font-weight:850;margin:5px 0}.up{color:var(--green)}.warn{color:var(--amber)}.sub{color:var(--muted);font-size:12px}.bar{height:9px;border-radius:9px;background:#1a2a35;overflow:hidden;margin:9px 0}.bar i{display:block;height:100%;border-radius:inherit;background:linear-gradient(90deg,var(--cyan),var(--green))}h2{font-size:16px;margin:0 0 12px}.rows{display:grid;gap:9px}.row{display:grid;grid-template-columns:1.25fr .75fr;gap:10px;padding-bottom:8px;border-bottom:1px solid #1e313d}.row:last-child{border:0;padding:0}.row b{text-align:right}.pill{display:inline-block;border:1px solid #315064;border-radius:999px;padding:4px 8px;color:#c8edf4;font-size:11px;margin:2px 3px 2px 0}table{width:100%;border-collapse:collapse;font-size:12px}th,td{padding:8px 7px;border-bottom:1px solid #203542;text-align:right}th:first-child,td:first-child{text-align:left}th{color:var(--muted);font-weight:600}.risk{border-left:3px solid var(--red);padding-left:11px}.good{border-left:3px solid var(--green);padding-left:11px}.timeline{display:grid;grid-template-columns:repeat(4,1fr);gap:8px}.event{background:var(--card2);border-radius:11px;padding:11px}.event b{display:block;color:var(--cyan);margin-bottom:4px}.foot{color:var(--muted);font-size:11px;margin-top:12px}@media(max-width:760px){.kpi,.wide,.side,.half{grid-column:1/-1}.top{display:block}.stamp{text-align:left;margin-top:8px}.timeline{grid-template-columns:1fr 1fr}}@media(max-width:460px){.timeline{grid-template-columns:1fr}.dash{padding:12px}}
NASDAQ · GENB · Live supply test
Generate Biomedicines
The stock is rallying before 103.14 million restricted shares become eligible for resale.
Market snapshot
August 25, 2026 · 12:36 EDT
Regular session open
August 25, 2026 · 12:36 EDT
Regular session open
Share price
$19.90
▲ 12.30% · +$2.18
Intraday range
$17.38–22.67
Record high reached intraday
Volume
3.16M
3.75× three-month average
Quoted market value
$2.55B
≈ $280M added today
Potential supply: the main investor variable
103.14M restricted shares · 80.4% of outstanding25.0M IPO sharesRestricted pool is 4.13× the IPO blockRestrictions expire following the August 25 close. Eligibility does not mean holders will sell; securities-law and affiliate limits still apply.
Price context
IPO price · Feb. 2026$16.00
Premium to IPO+24.4%
52-week low$11.00
52-week high$22.67
Average target$25.60
Target upside+28.6%
Analyst expectations
| Firm | Rating | Target | Upside |
|---|---|---|---|
| Morgan Stanley | Buy | $22 | 10.6% |
| Piper Sandler | Buy | $24 | 20.6% |
| H.C. Wainwright | Buy | $25 | 25.6% |
| Goldman Sachs | Buy | $26 | 30.7% |
| Guggenheim | Buy | $30 | 50.8% |
Six-analyst consensus: Strong Buy. Targets current through Aug. 25, 2026; upside uses $19.90.
Operating signal · Q2 2026
Collaboration revenue$6.3M −37.7% YoY
R&D expense$64.3M +7.7%
Net loss$67.3M +18.5%
H1 operating cash use$138.3M +35.7%
Cash + securities$457.4M
Management runwayInto H1 2028
Catalyst timeline
Feb. 27$400M IPO priced at $16; 25M shares sold.
Aug. 25 closeLock-up expires on 103.14M restricted shares.
Aug. 26Restricted holders may gain resale eligibility, subject to limits.
Sept. 8Phase 1 COPD data for GB-0895 at ERS Congress.
Bull case
Strong volume and a price above the $16 IPO level suggest buyers are absorbing the known supply event. The average analyst target still implies 28.6% upside. Phase 3 severe-asthma studies and near-term COPD data offer clinical catalysts.
Risk case
The eligible resale pool is more than four times the IPO block. Generate has no approved products or product-sales revenue. A disappointing trial result, faster cash use or broad holder selling could compress valuation and bring forward financing risk.
Sources: Generate Biomedicines Form 10-Q filed Aug. 6, 2026; company Q2 release; Reuters IPO report; Yahoo Finance and StockAnalysis market/analyst data. Live figures timestamped Aug. 25, 2026, 12:36 EDT. Calculations use 128.269M shares outstanding and the $19.90 snapshot.
Moderna Stock Jumps 12% as Wolfe Sees $9.2 Billion Intismeran Opportunity
Moderna shares jumped 12.2% on Tuesday after Wolfe Research abandoned its bearish rating. The move extended a volatile repricing of the vaccine maker's cancer pipeline.
NASDAQ: MRNA · STOCK MOVE
Moderna's oncology re-rating
Market snapshot: August 25, 2026, 11:25 EDT · U.S. regular session
+12.18% today
Share price
$155.81
Day range $141.21–$159.20
Trading volume
23.8M
1.80× 3-month daily average
Market value
$62.2B
399.2M shares outstanding
52-week position
88%
$22.28 low · $176.66 high
Session performance: company-specific buying
Prices from Yahoo Finance, captured August 25, 2026, 11:25 EDT.
Analyst targets versus $155.81
UBS
Neutral
$150Barclays
Equal Weight
$125Goldman
Neutral
$120Morgan Stanley
Equal Weight
$89JPMorgan
Underweight
$7723-analyst consensus$95.67 · Hold
S&P Global analyst snapshot, accessed August 25, 2026.
Balance-sheet bridge
Q2 revenue$145M · +2% YoY
Q2 net loss-$782M
Q2 R&D expense$651M · -7% YoY
June 30 cash + investments$6.9B
2026 revenue goalUp to +10%
Year-end cash guide$4.7B–$5.2B
Moderna Q2 2026 results, July 31, 2026.
Catalyst path
Aug. 19INTerpath-001 met its primary and key secondary endpoints. Detailed efficacy data remain pending.
Aug. 24Barclays lifted its target to $125 from $48 and kept Equal Weight.
Aug. 25Wolfe moved to Peer Perform and introduced a $9.2B four-indication peak-sales marker.
Next proofFull Phase 3 data, regulatory discussions, launch timing and personalized-manufacturing economics.
Vitruvias Thyroid Recall Spurs Potency Verifications for 1.5 Million Patients
A recall of a thyroid medication affecting only 1,955 distributed units is now serving as a key marker for pharmaceutical traceability. The move comes soon after the FDA renewed efforts to address unapproved animal-based thyroid treatments taken by about 1.5 million Americans.
:root{color-scheme:dark;--bg:#090d13;--panel:#111824;--panel2:#151f2d;--text:#edf3f8;--muted:#94a5b7;--line:#263548;--cyan:#55c7e8;--amber:#f5b84b;--red:#ff6b78;--green:#69d39a}*{box-sizing:border-box}body{margin:0;background:var(--bg);color:var(--text);font:14px/1.45 Inter,ui-sans-serif,system-ui,-apple-system,BlinkMacSystemFont,"Segoe UI",sans-serif}.dash{max-width:1120px;margin:auto;padding:24px}.eyebrow{color:var(--cyan);font-size:12px;font-weight:800;letter-spacing:.12em;text-transform:uppercase}.title{font-size:clamp(24px,4vw,40px);line-height:1.05;margin:7px 0 8px}.stamp{color:var(--muted);font-size:12px}.grid{display:grid;grid-template-columns:repeat(12,1fr);gap:14px;margin-top:18px}.card{background:linear-gradient(145deg,var(--panel),var(--panel2));border:1px solid var(--line);border-radius:16px;padding:16px;box-shadow:0 12px 36px #0005}.kpi{grid-column:span 3}.wide{grid-column:span 7}.side{grid-column:span 5}.full{grid-column:1/-1}.label{color:var(--muted);font-size:11px;font-weight:800;letter-spacing:.08em;text-transform:uppercase}.value{font-size:30px;font-weight:850;margin:5px 0}.sub{color:var(--muted);font-size:12px}.accent{color:var(--amber)}.good{color:var(--green)}.risk{color:var(--red)}h2{font-size:16px;margin:0 0 12px}table{width:100%;border-collapse:collapse}th,td{text-align:left;padding:9px 7px;border-bottom:1px solid var(--line);vertical-align:top}th{color:var(--muted);font-size:11px;text-transform:uppercase}tbody tr:last-child td{border-bottom:0}.bar{height:12px;border-radius:999px;background:#233044;overflow:hidden;margin:9px 0 4px}.bar span{display:block;height:100%;width:53.5%;background:linear-gradient(90deg,var(--cyan),var(--amber))}.timeline{display:grid;grid-template-columns:repeat(4,1fr);gap:8px}.event{border-left:3px solid var(--cyan);padding:8px 10px;background:#0b111a;border-radius:5px}.event b{display:block;font-size:12px}.event span{color:var(--muted);font-size:11px}.chip{display:inline-block;border:1px solid var(--line);border-radius:999px;padding:5px 8px;margin:3px;color:var(--muted)}.note{color:var(--muted);font-size:11px;margin-top:10px}.legend{display:flex;gap:14px;flex-wrap:wrap;color:var(--muted);font-size:11px}.dot{width:8px;height:8px;border-radius:50%;display:inline-block;margin-right:5px}.callout{border-left:3px solid var(--amber);padding-left:12px;color:#dce6ef}.sources a{color:var(--cyan);text-decoration:none}.sources a:hover{text-decoration:underline}@media(max-width:780px){.kpi,.wide,.side{grid-column:1/-1}.timeline{grid-template-columns:1fr 1fr}}@media(max-width:480px){.dash{padding:14px}.timeline{grid-template-columns:1fr}.value{font-size:26px}}
Thyroid-drug quality dashboard
Vitruvias potency recall: small lot, larger control test
Status verified August 25, 2026, 09:48 EDT / 15:48 CEST · U.S. market open
Units released
3,655
Lot 504950
Units sold
1,955
53.5% of released units
Not sold
1,700
46.5% · derived balance
Reported harm
0
Related adverse events as of Aug. 21
Distribution footprint
Share of released units sold
Sold 53.5%Not sold 46.5%
3,6551,955ReleasedSoldWhy potency matters
Testing found potential superpotency in a medicine containing levothyroxine and liothyronine. Excess hormone can trigger hypertension, chest pain, rapid heart rate or rhythm disturbances.
ElderlyPregnant womenInfants
FDA identifies synthetic levothyroxine as a narrow-therapeutic-index drug, where small dose differences can matter.
Recall timeline and control points
Jan. 31, 2025First distribution
Sept. 30, 2025Last distribution
Aug. 21, 2026Company announcement
Aug. 24, 2026FDA posting
Sector comparison
| Measure | Current / history | Reading |
|---|---|---|
| Vitruvias recall | 1 lot; 30 mg; potential superpotency | Contained footprint, consumer-level retrieval |
| Acella 2020 recall | 13 lots; 30/60/90 mg; up to 115% T3 | Potency failures have recurred in animal-derived thyroid products |
| Animal-derived users | 1.5m U.S. patients in 2024 | Meaningful niche under risk-based FDA enforcement |
| Synthetic levothyroxine users | 22m U.S. patients in 2024 | Much larger approved treatment base |
Investor transmission
| Manufacturers | Testing, destruction, investigation, corrective action |
| Distributors | Lot tracing, account notification, returns |
| Drug developers | Potential application and approval spending |
| Patients/providers | Replacement supply and clinical monitoring |
Watch: recall expansion, adverse-event reports, FDA classification, repeat potency findings.
Verified sources
FDA recall notice · FDA animal-derived thyroid policy · FDA narrow-therapeutic-index standards · FDA recall process
Derived figures: sold share = 1,955 ÷ 3,655; unsold balance = 3,655 − 1,955. FDA had not published a recall classification in the reviewed notice by the timestamp above.
Moderna Shares Drop 4% as $17 Billion Valuation Gap Challenges Cancer Vaccine-Fueled Surge
Shares of Moderna, Inc. dropped 4.3% on Monday, as investors weighed the extent to which a milestone cancer-vaccine result could sustain the company's value ahead of regulators reviewing the complete data.
Investor dashboard · NASDAQ: MRNA
Moderna’s cancer-vaccine valuation test
Science reset the probability. Full Phase 3 data must now justify the price.
Market closed
24 Aug 2026 · 16:30 EDT
24 Aug 2026 · 16:30 EDT
Close
$138.89
−4.30% Monday
Volume
31.50M
2.39× three-month average
Since Aug. 18
+120.6%
Pre-readout close: $62.96
Market value
$55.5B
Approx.; 399.24M shares
Five-session repricing
Closing priceAug. 19 volume: 199.25MAug. 24 volume: 31.50M
Valuation gap
Current price
$138.89
Consensus target
$95.67
−31.1% implied price gap. At current shares outstanding, that is about $17.3B of equity value.
Fresh analyst reset
| Firm | Rating | Target | Date |
|---|---|---|---|
| Barclays | Hold | $48 → $125 | Aug 24 |
| UBS | Hold | $50 → $150 | Aug 20 |
| Morgan Stanley | Hold | $39 → $89 | Aug 19 |
| Jefferies | Hold | $60 | Aug 19 |
| BofA | Hold | $40 → $170 | Aug 19 |
23-analyst consensus: Hold · range $25–$170
Catalyst and disclosure gap
| Trial | Phase 3 INTerpath-001; 1,137 patients |
|---|---|
| Combination | Intismeran autogene + Keytruda |
| Result | Both primary endpoints met |
| Known | RFS and DMFS statistically significant |
| Not yet disclosed | Hazard ratios, absolute curves, filing timetable |
| Next trigger | Medical-meeting presentation or regulatory guidance |
Fundamentals and runway
| Metric | 2026E | 2027E |
|---|---|---|
| Revenue | $2.11B | $2.46B |
| Growth | +8.35% | +16.66% |
| EPS | −$8.62 | −$4.58 |
Year-end 2026 cash forecast: $4.7B–$5.2B
Q2 GAAP net loss: about $0.8B. Operating-expense outlook improved by about $0.2B.
Investor decision map
| Scenario | What changes | Likely read-through |
|---|---|---|
| Bull | Large effect, clean safety, quick filing | Pipeline value broadens across tumors |
| Base | Clinically useful result, normal review | Wide target range persists |
| Bear | Modest effect or manufacturing friction | Premium over consensus compresses |
Sources and timestamps: price and volume at 24 Aug 2026, 16:30 EDT — StockAnalysis, Investing.com; analyst targets as of 24 Aug 2026 — StockAnalysis and The Fly/TipRanks; trial — company release; financials — Moderna IR. Calculations use unrounded inputs where available.
SELLAS Shares Build on 15% Surge Ahead of $2.98 Billion Pipeline Milestone
SELLAS Life Sciences Group, Inc. shares built on Friday’s 15.37% surge in premarket trade Monday, rising a further 1.62% to $15.71 at 08:40 EDT. The stock was 1.1% shy of its 52-week peak at $15.88.
NASDAQ · SLS
SELLAS catalyst dashboard
Market data timestamp: August 24, 2026, 08:40 EDT · U.S. premarket
$15.71+1.62% premarket
Friday: +15.37%
Friday close
$15.46
$2.06 daily gain
52-week high
$15.88
Premarket price is 1.1% below it
Market value
$3.12B
Based on Friday's close
Beta
2.49
High event-driven volatility
Five-session price path
Five-session gain: 18.9%. Friday volume reached 15.11 million, 2.8× Monday's turnover.
What the valuation assumes
$2.982B
Implied pipeline and other value after subtracting June cash from Friday's equity value.
Cash 4.4%Pipeline/other 95.6%
Catalyst clock
| Program | Status | Next event |
|---|---|---|
| GPS / REGAL Phase 3 | 78 of 80 events as of May 11 | 80th event → final analysis |
| SLS009 frontline AML | 28 of 80 patients enrolled | Topline Q4 2026 |
| SLS009 pancreatic | Preclinical | Conference data |
Street view
| Consensus | BUY |
| Average target | $32.50 |
| Maxim | $30 |
| Alliance Global | $35 |
Only two analysts comprise the cited consensus.
Balance-sheet buffer
$138.3M
Cash at June 30. Q2 net loss was $9.6 million; R&D expense was $6.3 million.
Dilution marker
+31.9%
Shares outstanding: 201.9 million at June 30, versus 153.1 million at December 31.
Why it is moving
Investors are front-running the REGAL event threshold and repricing the cancer-vaccine readout. Friday had no new SELLAS release, so expectation—not fresh clinical evidence—drove the move.
Risk frame
REGAL is a binary clinical catalyst with event-driven timing. A negative result could unwind much of the $2.98 billion non-cash premium. Delays, regulatory setbacks, rising trial costs and additional share issuance remain material.
Sources: SELLAS Q2 2026 corporate update and balance sheet; StockAnalysis / S&P Global Market Intelligence; Maxim and Alliance Global notes reported by The Fly via TipRanks. Pipeline value is an arithmetic estimate, not company guidance.
Eli Lilly unveils £110 Foundayo in UK, heightening focus on NHS hurdles
Eli Lilly and Company introduced Foundayo in pharmacies across Britain on Monday. The oral treatment for obesity debuts at about one-third the monthly private cost of Mounjaro.
NYSE:LLY · UK Foundayo launch
Private launch. Public-pay prize.
A £100–£120 monthly tablet opens Europe for Lilly. NHS reimbursement—not pharmacy availability—sets the scale.
$1,255.26-0.01% premarket
Observed 24 Aug 2026, 04:36 EDT
Prior close: $1,255.40 at 16:03:51 EDT, 21 Aug
Prior close: $1,255.40 at 16:03:51 EDT, 21 Aug
Expected monthly range
Midpoint price gap
First reported quarter
Trailing P/E
Q2 product scale · revenue
Illustrative UK gross run rate
£132m100k patients
£660m500k patients
£1.32bn1m patients
Annualised at £110 monthly. Scenario only; before discounts, dropouts, taxes and channel costs.
What the launch changes
Analyst mix · 28 ratings
22 Buy4 Hold2 Sell4.4% upside
Investor read-through
Britain validates the oral platform, but private-pay sales start small against a $86bn guidance midpoint. NICE access is the real volume gate.
What can break the case
Slow reimbursement, Novo competition, discontinuations, safety concerns or lower realised prices could expose a premium valuation.
Eli Lilly’s $67 Billion Surge Brings Shares Close to Wall Street’s Consensus Target
Eli Lilly and Company saw its market capitalization rise by about $67.1 billion over the past week. Shares climbed 6.38% to $1,255.40 as of Friday’s close, with 891.36 million shares outstanding. The stock now trades just 4.43% under the consensus one-year price target from Wall Street. The gap in valuation has rapidly closed.
Eli Lilly LLY
Obesity growth meets a narrow valuation cushion
$1,255.40 +0.88%
NYSE close · Aug. 21, 2026 · 4:00 p.m. EDT
Weekly return
+6.38%
vs. Aug. 14 close
Value added
≈$67.1B
preliminary; 891.36M shares
Market value
≈$1.12T
preliminary at Friday close
Avg. target upside
+4.43%
$1,311 consensus target
Five-session tape
Growth engine · Q2 2026
Total revenue: $22.97B, up 48%; volume +60%, realized price -13%.
Analyst target range
Consensus: Buy · 29 analysts · median target $1,372
Why the stock moved
A post-earnings rerating met fresh bullish targets. Investors priced in 48% quarterly sales growth, $85B-$87B guidance and a deeper obesity pipeline. Thursday's reversal showed how quickly profit-taking appears near records.
The investor read: operating growth remains rare, but the average target now offers only 4.43% upside. Future gains need better-than-guided volume, successful factory ramp-ups or another pipeline surprise.
Support
$1,243.23Thursday low
Record marker
$1,292.65Wednesday intraday high
Next macro check
U.S. income & inflationBEA release calendar this week
Market data: StockAnalysis / S&P Global, through Aug. 21, 2026, 4:00 p.m. EDT. Analyst consensus: S&P Global via StockAnalysis. Financials and guidance: Eli Lilly Q2 release. Market value estimates use 891.36 million shares outstanding and may differ from vendor calculations.
Capricor’s FDA Delay Leaves a $2.20-a-Share Bet on Deramiocel
Capricor Therapeutics, Inc. ended Friday with only about $2.20 per share of equity value above its June cash. That preliminary figure frames the wager on deramiocel after regulators delayed their decision.
NASDAQ: CAPR · Event-driven biotech
Deramiocel: more review, more runway risk
Market data through August 21, 2026, 4:00 p.m. EDT · Financial data through June 30, 2026
$6.29
−8.04% Friday
After hours: $6.38 at 7:59 p.m. EDT
Cash per share
$4.09
June cash ÷ 58.1m reported shares
Price above cash
$2.20
Preliminary; not liquidation value
Market cap
$365.5m
Friday close × June share count
Target range
$2–$28
Consensus Hold · median $6
Six-session repricing
August 14 volume reached 66.3m shares. Friday volume was 8.3m, while the close sat 5.4% below August 14.
Regulatory evidence stack
Bar lengths are visual emphasis, not probabilities. The committee vote was advisory and nonbinding.
Cash versus burn
| Metric | 2026 | Comparison |
|---|---|---|
| Cash & securities | $237.9m | −$80.2m in H1 |
| Q2 operating expense | $42.9m | +55.0% YoY |
| Q2 net loss | $40.7m | +57.2% YoY |
| Runway at H1 loss pace | ~19 months | Preliminary |
Company guidance: resources fund at least the next 12 months.
Analyst recommendation map
| Firm | Action | Rating | Target | Versus $6.29 |
|---|---|---|---|---|
| Cantor Fitzgerald | Upgrade | Buy | $28 | +345% |
| Piper Sandler | Maintain | Hold | $2 | −68% |
| B. Riley | Maintain | Hold | $5 | −21% |
| Consensus | — | Hold | $10.50 avg. | +67% |
| Median | — | — | $6 | −5% |
Wall Street Targets Trail Moderna as Cancer-Vaccine Surge Continues
Moderna, Inc. closed the week, its best in years, at $145.13. The biotech company's shares climbed 8.9% on Friday, following a near-tripling of the stock's value on Wednesday and a sharp drop on Thursday. From August 14, the five-day rally amounted to a 129.2% increase.
NASDAQ · MRNA
The cancer-vaccine rerating
Market data as of August 21, 2026, 16:00 EDT (22:00 CEST). U.S. market closed.
Friday close
$145.13
+8.86% Friday
Five-session move
+129.2%
From $63.32 on Aug. 14
Friday volume
86.7M
6.7× 3-month daily average
Market value
$57.9B
399.2M shares outstanding
Five-session price shock
Why the stock moved
Phase 3 crossed the lineIntismeran plus Keytruda met recurrence-free and metastasis-free survival endpoints.
First-of-kind proofThe companies called it the first positive Phase 3 result for an individualized neoantigen therapy.
Short squeeze amplified itS3 estimated a $5.5 billion one-day mark-to-market loss for short sellers.
Full data remain pendingNo Phase 3 hazard ratios or overall-survival figures were disclosed.
Analyst targets after the readout
| Firm | Rating | Target | Gap |
|---|---|---|---|
| BofA | Hold | $170 | +17.1% |
| UBS | Hold | $150 | +3.4% |
| Goldman | Hold | $120 | -17.3% |
| Morgan Stanley | Hold | $89 | -38.7% |
| Consensus | Neutral | $78.78 | -45.7% |
Clinical and financial bridge
| Phase 3 patients | 1,137 |
| Prior Phase 2b recurrence/death reduction | 49% |
| Q2 revenue | $145M |
| Q2 GAAP net loss | $782M |
| June cash and investments | $6.9B |
| 2026 year-end cash outlook | $4.7B-$5.2B |
What matters next
Detailed Phase 3 data
Highest-impact catalyst
Regulatory path
Approval discussions and timing
Commercial economics
Personalized manufacturing, pricing and margin
Sources: Moderna and Merck Phase 3 release, Moderna Q2 2026 SEC filing, Nasdaq/Yahoo Finance closing data, Investing.com analyst targets, S3 Partners estimate reported by Business Times. Percentages are calculated from cited closes and targets. This dashboard is informational, not investment advice.
SELLAS Shares Gain $416 Million With REGAL Trial Approaching Final Analysis
SELLAS Life Sciences Group, Inc. ended Friday at $15.46, marking a 15.4% increase. Based on its share count as of June 30, the gain represents an approximate $416 million boost in market capitalization. The figure is provisional, as the number of outstanding shares may have varied since the end of the quarter.
NASDAQ:SLS · Weekend investor dashboard
$416M added without new company data
SELLAS' rally now rests on an event-driven Phase 3 survival readout. Cash is meaningful, but it explains only 4.4% of market value.
Market closed · Data through August 21, 4:00 p.m. EDT
Friday close
$15.46
+15.4% · 2.6% below 52-week high
Estimated value added
$416M
Friday · June 30 share count
Market capitalization
$3.12B
22.6× reported cash
Cash
$138.3M
June 30 · 4.4% of market value
Three-week repricing
SLS gained 54.4% across three consecutive winning weeks.
Valuation split
What Friday's equity value represents
No product revenue was reported for the first half of 2026.
The binary center
REGAL is event-driven; the date cannot be fixed.
Success path
Statistically significant, clinically meaningful survival could support a potential BLA filing.
Failure path
A missed survival endpoint would remove the main late-stage pillar beneath valuation.
127 patients
Actual enrollmentRandomized Phase 3 AML maintenance study
80th death
Final-analysis triggerDatabase lock, review, unblinding, topline disclosure
Cash came with dilution
Six months ended June 30, 2026
Oncology momentum and analyst expectations
Weekly stock moves use August 14–21 closes. Targets are current S&P Global consensus data.
| Company | Weekly move | Consensus | Analysts | Average target | Implied return |
|---|---|---|---|---|---|
| Moderna · NASDAQ:MRNA | +129.2% | Hold | 23 | $91.39 | -37.0% |
| SELLAS · NASDAQ:SLS | +21.0% | Buy | 2 | $32.50 | +110.2% |
| Merck · NYSE:MRK | +12.3% | Buy | 28 | $147.77 | -3.1% |
| ImmunityBio · NASDAQ:IBRX | +2.9% | Strong Buy | 4 | $12.75 | +63.7% |
Next checkpoints
Event-driven
REGAL 80th eventNo fixed announcement date
Q4 2026
SLS009 topline dataFront-line AML study
Upcoming
Pancreatic preclinical dataMedical conference planned
Risk lens
REGAL could miss its survival endpoint or face regulatory demands for more evidence. SLS009 remains early. Warrant exercises and future equity sales can dilute holders. A reversal in cancer-vaccine sentiment could erase gains before company-specific data arrive.
Stock data: August 21, 2026, 4:00 p.m. EDT. Dashboard status: August 22, 2026, 6:24 a.m. EDT. Sources: SELLAS SEC filings; ClinicalTrials.gov; Yahoo Finance; StockAnalysis. Peer programs differ in platform, indication and stage.
Moderna Shares (NASDAQ:MRNA) Finish Landmark Week, Surging 70% Over Wall Street Consensus
Moderna, Inc. closed its most turbulent week since the pandemic at $145.13. The stock rose 8.86% on Friday, following two days of sharp gains and losses. After-hours trading added a further 0.43%, bringing shares to $145.75.
Moderna · NASDAQ:MRNA
Endpoints met.
The valuation ran ahead.
Official close: August 21, 2026, 16:00:01 EDT
Nasdaq · U.S. dollars
Nasdaq · U.S. dollars
Friday close
$145.13▲ 8.86%
Day range $132.42–$159.47 · Volume 86.74M vs. 15.08M average
15-analyst average target
$85.46
41.1% below Friday's close
Consensus: 2 Buy · 12 Hold · 1 Sell
Since Tuesday+130.5%
$62.96 before the readout to $145.13 Friday.
Equity value added≈$32.81B
$82.17 per share × 399.24M shares.
Current market cap$57.94B
About 8.4× June cash and investments.
June liquidity$6.90B
Before the $950M litigation payment made in July.
Three-session repricing
Analyst target map
Bank of America · Alec StranahanHOLD $170
UBS · Michael YeeHOLD $150
RBC Capital · Luca IssiHOLD $130
Goldman Sachs · Salveen RichterHOLD $120
J.P. Morgan · Jessica FyeSELL $77
Only Bank of America's $170 target sits clearly above Friday's close. UBS's $150 target leaves 3.4% upside.
What the market has—and has not—seen
INTerpath-001 enrolled 1,137 melanoma patients and met recurrence-free and distant-metastasis-free survival endpoints. No new safety signal emerged. The full Phase 3 hazard ratios, confidence intervals, subgroup results and overall-survival data remain undisclosed. Investors have added $32.81 billion of equity value without the effect size.
Next proof points
- Full data at an international medical meeting
- Regulatory filing timeline
- Manufacturing economics for personalized doses
- Success beyond melanoma across nine Phase 2/3 studies
- 50/50 profit split with Merck
Risk: the price can reverse if detailed efficacy, safety or regulatory timing falls short of the expectations embedded in the rally.
Sources: Google Finance · Phase 3 release · SEC Q2 filing
Capricor Stock Faces Securities-Fraud Case as FDA Review Stays Open
Capricor Therapeutics faces a renewed legal overhang after law firms on Thursday repeated a September 28 lead-plaintiff deadline in a federal securities-fraud case. The complaint covers buyers from December 17, 2025, through July 26, 2026.
NASDAQ: CAPR · Litigation + FDA monitor
Capricor Therapeutics
Securities-fraud case adds a legal layer to a regulatory binary.
$6.84Close · Aug. 20, 2026, 4:00 PM EDT
Pre-market unchanged at 9:00 AM EDT, Aug. 21
Pre-market unchanged at 9:00 AM EDT, Aug. 21
Since July 24−65.3%
Cash & securities$237.9m
Cash / market cap59.9%
Static runway5.5 qtrs
The repricing
Verified closing milestonesJuly FDA shock
Event clock
FDA documents
Analysis and efficacy concerns surface.
Panel vote
9-3 against efficacy evidence.
New-data path
FDA willing to review 24-month amendment.
Legal deadline
Lead-plaintiff motion due.
Cash buffer versus burn
Cash / market cap59.9%
Cash decline−25.2%
Q2 opex growth+54.9%
Static runway: $237.9m cash ÷ $42.9m Q2 operating expenses = 5.5 quarters. This is a simple ratio, not management guidance.
Analyst recommendations
| Firm | Date | Rating | Target |
|---|---|---|---|
| Cantor Fitzgerald | Aug. 14 | Overweight | $28 |
| B. Riley | Jul. 31 | Hold | $5 |
| Jones Trading | Jul. 30 | Hold | — |
| Piper Sandler | Jul. 30 | Neutral | $2 |
| H.C. Wainwright | Jul. 30 | Neutral | — |
Investor read-through
The FDA amendment timetable matters more than repeated legal notices.
The lawsuit mirrors the same statistical-analysis dispute that drove the stock collapse. A revised action date would clarify how much regulatory optionality remains.
Downside watch
A new clinical-trial requirement could extend losses and consume the cash buffer. Adverse discovery in the securities case may add cost and disclosure risk. Faster spending would shorten the 5.5-quarter static runway.
Sources: Google Finance, Capricor Q2 release, FDA, Reuters, and published analyst actions. Market value uses $397.38m at the August 20 close. All calculations are transparent derivatives of cited figures.
BioNTech jumps $5.1 billion in premarket; analyst target now just 8% higher
BioNTech SE retained the majority of a $5.1 billion rise in market value following positive data from a competing cancer vaccine. Shares ended Thursday at $110.89, a decline of 1.97% after surging 21.96% on Wednesday.
NASDAQ:BNTX · Event read-through
A $5.1bn rally before BioNTech's own proof
Moderna and Merck validated the category. BioNTech kept most of the sympathy gain, compressing the gap to the existing analyst consensus.
Price: $110.89
Aug. 20, 2026 · 16:00 EDT
U.S. regular close
Aug. 20, 2026 · 16:00 EDT
U.S. regular close
Event-day move
+21.96%
Aug. 19 close: $113.12
Value added
$5.12bn
Estimate using 251.2m shares
Volume shock
9.1×
8.61m vs 0.945m recent average
Gain retained
89%
Through Aug. 20 close
Analyst targets: rally consumed the cushion
Average target implies 8.4% upside; targets predate the Aug. 19 rally.
Capital to fund the test
Q2 revenue: €105.6m · IFRS net loss: €820.8m
What the market validated—and what it did not
| Program | Stage | Evidence | Investment read |
|---|---|---|---|
| Moderna/Merck intismeran | Phase 3 | Positive topline in 1,137 resected melanoma patients | Direct category validation |
| BioNTech BNT111 | Phase 2 | Positive response-rate endpoint vs historical control | Promising, not registrational proof |
| BioNTech autogene cevumeran | Phase 2 | Missed primary PFS endpoint in advanced melanoma | Platform outcomes can diverge |
Investor lens
The market has already paid BioNTech for part of the platform validation. At $110.89, the pre-rally analyst average is only 8.4% higher. The next durable leg likely needs BioNTech-specific efficacy.
Risk check
Detailed peer data are still pending. Manufacturing, regulation and reimbursement remain unresolved. BioNTech's own trials may not reproduce Moderna's result.
Sources: Yahoo Finance, Reuters, BioNTech Q2 2026, S&P Global analyst poll via StockAnalysis. Market-value estimate uses the latest reported 251.2m shares. Analyst targets and consensus are estimates, not guarantees.
Moderna Market Value Rises $28 Billion in a Week, Trading at Ninefold Melanoma Forecast
Moderna, Inc. has increased its market value by roughly $28 billion in the past week. This surge suggests investors' expectations extend beyond the potential of melanoma treatment.
Moderna investor dashboard
The $28bn repricing
A positive Phase 3 melanoma result validated the science. The valuation now assumes a broader oncology platform.
NASDAQ · MRNA
Aug. 20 close
$133.32
▼ 23.55% Thursday
4:00:01 p.m. EDT, Aug. 20, 2026
Weekly close gain
+110.5%
From $63.32 on Aug. 14
Market value added
$27.9bn
Price change × 399.24m shares
Premarket snapshot
$139.10
▲ 4.33%
4:33 a.m. EDT, Aug. 21, 2026
Two-day price shock
Wednesday added about $44.5bn; Thursday erased about $16.4bn.
Valuation bridge
Weekly value gain$27.9bn
2035 melanoma sales estimate$3.0bn
Implied multiple9.3×
Profit economics50 / 50 with Merck
The stock move requires value from other tumors, durable pricing, or both.
Trial scorecard
Phase3
Patients1,137
RFSMet
DMFSMet
Numeric efficacyNot released
Balance-sheet runway
June cash + investments$6.9bn
Q2 revenue$145m
Q2 net loss-$782m
July settlement payment-$950m
Cash was $7.5bn at March 31.
Analyst map
Buy / Hold / Sell2 / 12 / 1
Average target$82.62
Vs. Aug. 20 close-38.0%
Target range$40–$170
Consensus has not caught the stock.
What must happen next
| Checkpoint | Current state | Why it matters |
|---|---|---|
| Full Phase 3 data | Topline only | Tests the size and durability of benefit |
| Regulatory path | Discussions planned | Sets filing timing and evidence burden |
| Other tumors | Eight-trial program | Needed to support platform valuation |
| Manufacturing | Individualized | Determines speed, scale and margins |
Risk lens
Data detailFDA timingManufacturingMelanoma uptakeCash burnThe scientific milestone is real. The commercial case is still preliminary.
Market data: Google Finance, captured Aug. 21, 2026 at 4:33 a.m. EDT; closing timestamp shown above. Historical Aug. 14 close: StockAnalysis. Trial data: Moderna and Merck, Aug. 19, 2026. Sales estimate: Barclays via Reuters. Financial data: Moderna Q2 2026 release. Calculations may differ slightly due to rounding.
Moderna Wipes Out $15.8 Billion, Shares Remain 63% Over Analyst Price Estimates
Moderna, Inc. dropped $39.64 per share on Thursday, wiping out around $15.8 billion in market capitalization. Despite the 22.7% decline, its price of $134.74 stayed 63% higher than the analysts’ average target of $82.62. The U.S. markets remained open.
NASDAQ:MRNA • Investor dashboard
Moderna: the post-trial valuation gap
Positive Phase 3 melanoma data met a market still waiting for magnitude, timing and price.
Market data: August 20, 2026, 15:30:24 EDT (21:30:24 CEST). U.S. cash market open.
Share price
$134.74
▼ $39.64 • 22.73%
Intraday range $128.61–$155.00
Previous close $174.38
Previous close $174.38
Two-session price bridge
Thursday erased an estimated $15.8B, but roughly $28.7B of Wednesday’s gain remained.
Valuation
$53.79B
Market capitalization
Turnover
85.67M
Volume • 8.6× recent average
52-week range
$22.28
Low • high $176.66
Move vs. pre-data*
+114%
Premium still retained
Analyst target gap
Current price$134.74
Consensus target$82.62
Price sits 63% above the average target
Target range: $40–$170
2 Buy12 Hold1 Sell
What the Phase 3 result established
Patients1,137
Recurrence-free survivalEndpoint met
Distant-metastasis-free survivalEndpoint met
Overall survivalNot yet available
New safety signalsNone reported
Financial runway
Q2 revenue$145M
Q2 GAAP EPS-$1.97
Q2 net loss-$782M
Expected year-end cash$4.7B–$5.2B
2026 revenue outlookUp to 10% growth
Investor checkpoint
The price now discounts execution. Full hazard ratios, safety detail, regulatory timing, personalized-manufacturing scale and reimbursement will decide whether the premium holds.
About 36% of Wednesday’s estimated price gain was erased Thursday.
TechStock² Updates
